Pfizer Inc. (NYSE:PFE) hasn’t performed well in recent years, with its stock declining more than 26% over the past decade.

Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

Pfizer Inc. raised the lower end of its earnings forecast for the year and reiterated its sales expectations despite unfavorable currency trends. The drugmaker continues to project its new Covid ...

Pfizer Reports Solid Q4 Earnings But Offers Weaker Outlook Stock undervalued as recent weak performance doesn’t reflect long-term outlook.

Pfizer (PFE) is set to release its Q4 2023 results amid rising bearish bets on its earnings outlook due to headwinds against its COVID-19 franchise. Read more here.

Pfizer reported third-quarter revenue and adjusted profit that blew past expectations. The company hiked its full-year outlook as its Covid vaccine and antiviral pill Paxlovid helped boost sales ...

Pfizer reaffirmed its 2025 outlook of $61 to $64 billion in revenue and adjusted earnings per share of $2.80 to $3. StockStory aims to help individual investors beat the market.

We think PFE stock may see higher levels post Q3 announcement on a revenue and earnings beat. If the company were to raise its full-year outlook, it will likely bode well with the investors.

Pfizer said Tuesday it now expects 2024 adjusted earnings between $2.45 a share to $2.65 a share, 30 cents higher at the midpoint than its prior projection. The shares rose as much as 1.4% at the ...

Pfizer (PFE) delivered earnings and revenue surprises of 43.75% and 0.88%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

While the COVID-19 pandemic is an increasingly distant memory for most investors, Pfizer (NYSE: PFE) has struggled to move past the overhang of record vaccine sales and earnings in 2021 and 2022 ...